BLOCKStrain Technology (TSXV:DNAX) CEO Robert Galarza believes that 2019 will be the year of refinement for Canada’s cannabis industry and that the bar will be raised across the seed-to-sale supply chain.

In an interview conducted at this year’s Cantech Investment Conference in Toronto, Galarza discussed the company’s partnership with WeedMD (TSXV:WMD,OTCQX:WDDMF,FWB:4WE) for the development of a first-of-its-kind genetics validation solution. He also outlined how BLOCKStrain’s solutions can support licensed producers in addressing the bottleneck for getting products to 


Below is a transcript of our interview with BLOCKStrain CEO Robert Galarza. It has been edited for clarity and brevity.

Investing News Network: Can you tell us about the validation testing program you are conducting with WeedMD.

BLOCKStrain CEO Robert Galarza: We have embarked upon a first-of-its-kind genetics validation solution with WeedMD, whereby the cannabis strains in their inventory have been genetically verified and recorded. Now, when purchased, any WeedMD product can be tested to make sure that it matches up with what we have recorded.

INN: What is the potential of the Genome-to-Sale software?

RG: Our entire solution is based on transparency and trust of inventory. One of the biggest problems in the industry is being able to understand if, as a consumer, you get what you pay for. By obtaining genetic data, we can push it into our system and into third-party track-and-trace partners to provide better visibility of that product all the way through to sale.

INN: What changes do you foresee for the cannabis space?

RG: In my opinion, 2018 was the year of inception. 2019 is the year of refinement. When it comes to production and supply, we are going to find ways to raise the bar and standards across the board. Companies like ours are part of a larger ecosystem that will enable that. We will be able to support producers that are doing their best to get high-quality product into the marketplace.

INN: How will BLOCKStrain’s products allow companies to scale in the future?

RG: When a company is looking to scale its business, some of the biggest problems are administrative burdens. There is a significant bottleneck that exists in the marketplace when a product is being tested and put out to market. We have chatted with producers that have had batches put to waste because the paperwork was lost.

As you grow in scale, all those administrative processes have to be digitized and recorded in an electronic fashion, making it much more efficient than what we’re currently seeing.

CEO interviews are part of investor education campaigns for clients advertising on the Investing News Network. Important news is contextualized by CEOs, and the resulting interviews are disseminated to the Investing News Network audience because they have value to market watchers.

The Investing News Network interviews a CEO for an understanding of their perspective on the company, the investment potential of the company and market news related to the company. The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. 

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less